PHYSICA TECHNOLOGY

Why collaborate?

By applying our know-how and technology to a drug, we can provide solutions for the following challenges:

• New Chemical Entities
  
  Rescuing R&D abandoned projects
  Innovative new chemical entities may be abandoned due to poor pharmacokinetic properties such as poor water solubility, poor gastric permeability and/or short therapeutic half-life. Through Physica's drug delivery systems, pharmacokinetic characteristics of a drug may be improved without altering pharmacodynamic properties.
  
  
• Marketed Drugs
  
  Enhance product life cycle management
  As soon as a drug substance's patent expires, a number of generic products will come on the market and decrease the originator company's profits. The most effective way to enhance the life cycle of a branded product is the introduction of a novel innovative dosage form. Physica can "optimize" a drug and permits the launch of a second generation medicine.
  
  Differentiate a product in a crowded market
  A product is challenged by a lack of differentiation? Then, an effective way of enhancing your competitiveness could be through the development of alternative drug delivery systems.
  
  

Collaboration steps

Physica has a step-by-step approach as described below:

1. Theoretical evaluation

After the signature of a Confidentiality Agreement, the client should fill in a Drug Data Sheet. We then review the physicochemical data of the compound and provide an indication of a formulation strategy, plus a feasibility study proposal, which contains also the cost and timing.

This stage takes 1- 2 weeks.

2. Feasibility study

Using the information from the above, formulation prototypes is identified and candidates are designed to meet the client's requirements for in vivo/in vitro preclinical testing.

This stage takes about 2- 4 months.

3. Development phase

If the client is satisfied with the prototypes produced during the feasibility study, the company enters into a development agreement. The prototype formulations are optimized and developed. The development phase includes formulation and analytical development, supporting stability and production of clinical batches.

This phase takes between 6 and 9 months.